Company Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
59.82 ^USD	-5.94%		-5.45%	-9.90%

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI

Business description: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Number of employees: 711

Sales by Activity: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Nanotechnology	138M	243M	241M	-	829M

See all business segments

Geographical breakdown of sales: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	138M	243M	241M	-	829M

See all geographic segments

Executive Committee: Arrowhead Pharmaceuticals, Inc.

Manager	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	56	30/11/2007
Daniel Apel DFI	Director of Finance/CFO	-	12/05/2025
Peter Carignan CTO	Chief Tech/Sci/R&D Officer	-	31/07/2022
Patrick O'brien CMP	Compliance Officer	62	30/11/2014
James Hamilton CTO	Chief Tech/Sci/R&D Officer	48	31/01/2025

See ARROWHEAD PHARMACEUTICALS, INC. governance

Composition of the Board of Directors: Arrowhead Pharmaceuticals, Inc.

Director	Title	Age	Since
Christopher Anzalone CHM	Chairman	56	-
Mauro Ferrari BRD	Director/Board Member	66	18/08/2010
Michael Perry BRD	Director/Board Member	66	18/12/2011
William Waddill BRD	Director/Board Member	68	31/12/2017
Adeoye Olukotun BRD	Director/Board Member	81	31/08/2020
Victoria Vakiener BRD	Director/Board Member	62	01/05/2022
Hong Bo Lu BRD	Director/Board Member	55	31/03/2024
Douglas Ingram BRD	Director/Board Member	63	05/02/2025

Composition of the Board of Directors

Shareholders: Arrowhead Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 14.94 %	20,293,888	14.94 %	1 407 M $
Vanguard Fiduciary Trust Co. 11.25 %	15,293,121	11.25 %	1 060 M $
Avoro Capital Advisor LLC 7.819 %	10,625,000	7.819 %	737 M $
Fidelity Management & Research Co. LLC 4.799 %	6,520,408	4.799 %	452 M $
STATE STREET CORPORATION 4.713 %	6,403,830	4.713 %	444 M $

List of ARROWHEAD PHARMACEUTICALS, INC. shareholders

Company details: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard

91105, Pasadena

+626 304 3400

http://www.arrowheadpharma.com

address Arrowhead Pharmaceuticals, Inc.(ARWR)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARROWHEAD PHARMACEUTICALS, INC.	-5.94%	-5.45%	+238.54%	+94.28%	8.38B
ARGENX SE	-0.61%	-5.35%	+7.61%	+93.47%	44.16B
WUXI APPTEC CO., LTD.	+0.92%	-4.81%	+49.57%	+13.78%	40.5B
INSMED INCORPORATED	-2.40%	-6.16%	+86.79%	+581.90%	30.21B
BIONTECH SE	-0.44%	-7.92%	-8.42%	-22.84%	25.47B
WUXI BIOLOGICS (CAYMAN) INC.	+2.54%	-9.65%	+54.31%	-36.52%	19.22B
GENMAB A/S	-2.62%	-6.49%	+5.33%	-32.35%	16.5B
AKESO, INC.	+5.20%	+0.37%	+49.24%	+146.95%	12.64B
SUMMIT THERAPEUTICS INC.	+1.14%	-8.92%	-20.43%	+987.05%	11.72B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.43%	-0.31%	+53.50%	-	11.51B
Average	+0.22%	-5.11%	+51.60%	+202.86%	22.03B
Weighted average by Cap.	+0.06%	-5.17%	+40.31%	+165.99%